204 related articles for article (PubMed ID: 11566974)
1. Activity of the ketolide antibacterial telithromycin against typical community-acquired respiratory pathogens.
Felmingham D; Zhanel G; Hoban D
J Antimicrob Chemother; 2001 Sep; 48 Suppl T1():33-42. PubMed ID: 11566974
[TBL] [Abstract][Full Text] [Related]
2. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin.
Felmingham D
J Infect; 2002 Feb; 44 Suppl A():3-10. PubMed ID: 12150493
[TBL] [Abstract][Full Text] [Related]
3. Clinical management of respiratory tract infections in the community: experience with telithromycin.
Quintiliani R
Infection; 2001 Dec; 29 Suppl 2():16-22. PubMed ID: 11785852
[TBL] [Abstract][Full Text] [Related]
4. Comparative activity of telithromycin against typical community-acquired respiratory pathogens.
Buxbaum A; Forsthuber S; Graninger W; Georgopoulos A
J Antimicrob Chemother; 2003 Sep; 52(3):371-4. PubMed ID: 12888585
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy of new antibacterial therapies in at-risk populations.
Lorenz J
J Infect; 2002 Feb; 44 Suppl A():25-30. PubMed ID: 12150492
[TBL] [Abstract][Full Text] [Related]
6. Activity of telithromycin, a new ketolide antibacterial, against atypical and intracellular respiratory tract pathogens.
Hammerschlag MR; Roblin PM; Bébéar CM
J Antimicrob Chemother; 2001 Sep; 48 Suppl T1():25-31. PubMed ID: 11566973
[TBL] [Abstract][Full Text] [Related]
7. Telithromycin: the first ketolide antibacterial for the treatment of community-acquired respiratory tract infections.
Lorenz J
Int J Clin Pract; 2003; 57(6):519-29. PubMed ID: 12918892
[TBL] [Abstract][Full Text] [Related]
8. Comparative in vitro activity of telithromycin and beta-lactam antimicrobials against bacterial pathogens from community-acquired respiratory tract infections: data from the first year of PROTEKT (1999-2000).
Kohno S; Hoban D;
J Chemother; 2003 Aug; 15(4):335-41. PubMed ID: 12962361
[TBL] [Abstract][Full Text] [Related]
9. From macrolides to ketolides: What is available for the treatment of outpatient respiratory tract infections?
Carter PL
Postgrad Med; 2002 Sep; 112(3 Suppl):18-25. PubMed ID: 19667591
[TBL] [Abstract][Full Text] [Related]
10. Clinical and bacteriological efficacy of the ketolide telithromycin against isolates of key respiratory pathogens: a pooled analysis of phase III studies.
Low DE; Brown S; Felmingham D
Clin Microbiol Infect; 2004 Jan; 10(1):27-36. PubMed ID: 14706083
[TBL] [Abstract][Full Text] [Related]
11. Antibacterial resistance among children with community-acquired respiratory tract infections (PROTEKT 1999-2000).
Felmingham D; Farrell DJ; Reinert RR; Morrissey I
J Infect; 2004 Jan; 48(1):39-55. PubMed ID: 14667791
[TBL] [Abstract][Full Text] [Related]
12. Overcoming antimicrobial resistance: profile of a new ketolide antibacterial, telithromycin.
Leclercq R
J Antimicrob Chemother; 2001 Sep; 48 Suppl T1():9-23. PubMed ID: 11566972
[TBL] [Abstract][Full Text] [Related]
13. Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin.
Fogarty CM; Kohno S; Buchanan P; Aubier M; Baz M
J Antimicrob Chemother; 2003 Apr; 51(4):947-55. PubMed ID: 12654763
[TBL] [Abstract][Full Text] [Related]
14. Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Germany and activity of the Ketolide Telithromycin: results from the PROTEKT surveillance study (1999-2000).
Reinert RR; Rodloff AC; Halle E; Baer W; Beyreiss B; Seifert H; Wichelhaus TA; Maass M; Mehl M
Chemotherapy; 2004 Jun; 50(3):143-51. PubMed ID: 15272227
[TBL] [Abstract][Full Text] [Related]
15. [Multicenter study in southern South America of the in vitro activity of telithromycin in strains with defined resistance phenotypes isolated from community-acquired respiratory infections].
Casellas JM; Visser M; Mac Dougall N; Coco B; Tomé G; Gliosca L;
Rev Esp Quimioter; 2001 Sep; 14(3):269-74. PubMed ID: 11753448
[TBL] [Abstract][Full Text] [Related]
16. Microbiological profile of telithromycin, the first ketolide antimicrobial.
Felmingham D
Clin Microbiol Infect; 2001; 7 Suppl 3():2-10. PubMed ID: 11523558
[TBL] [Abstract][Full Text] [Related]
17. Use of cethromycin, a new ketolide, for treatment of community-acquired respiratory infections.
Hammerschlag MR; Sharma R
Expert Opin Investig Drugs; 2008 Mar; 17(3):387-400. PubMed ID: 18321237
[TBL] [Abstract][Full Text] [Related]
18. Telithromycin: a new ketolide antimicrobial for treatment of respiratory tract infections.
Yassin HM; Dever LL
Expert Opin Investig Drugs; 2001 Feb; 10(2):353-67. PubMed ID: 11178347
[TBL] [Abstract][Full Text] [Related]
19. In vitro activities of the ketolides ABT-773 and telithromycin and of three macrolides against genetically characterized isolates of Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae and Moraxella catarrhalis.
Schmitz FJ; Schwarz S; Milatovic D; Verhoef J; Fluit AC
J Antimicrob Chemother; 2002 Jul; 50(1):145-8. PubMed ID: 12096026
[No Abstract] [Full Text] [Related]
20. Global surveillance through PROTEKT: the first year.
Grüneberg RN
J Chemother; 2002 Jul; 14 Suppl 3():9-16. PubMed ID: 12418556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]